A drug selected for the latest round of Medicare drug price negotiations stands to get dropped because a lower-cost biosimilar version of it is slated to hit the market this year.
Medicare selects Botox and Trulicity among 15 high-cost drugs for price negotiations under new federal authority, with lower prices expected in 2028.
The federal government has expanded its drug price negotiation program for seniors, adding more than a dozen high-cost medicines ...
Opinion
The Federal Government’s Drug Price Negotiation Program Would Likely Violate Its Own Antitrust Laws
A recent U.S. Court of Appeals for the Third Circuit ruling upholding the federal Inflation Reduction Act (IRA)’s drug price negotiation program has been appealed to the U.S. Supreme Court, one of ...
The 2028 negotiation cycle marks another major inflection point in the implementation of the Medicare Drug Price Negotiation Program—its first year incorporating Part B drugs and its first opportunity ...
President Donald Trump’s approach to lowering drug prices has leaned heavily on executive orders and voluntary deals with drugmakers, rather than legislation. (Andrew Harnik / Getty Images) As ...
This article is the latest in the Health Affairs Forefront featured topic, “Health Policy at a Crossroads,” produced with the support of the Commonwealth Fund and the Robert Wood Johnson Foundation.
As President Donald Trump touts new deals to cut the cost of blockbuster drugs like Wegovy and Zepbound, he’s barely mentioned Medicare’s drug price negotiation program — even though the government is ...
As President Donald Trump touts new deals to cut the cost of blockbuster drugs like Wegovy and Zepbound, he’s barely mentioned Medicare’s drug price negotiation program — even though the government is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results